Stage-dependent EZH2 methylation correlates with immune polarization, metabolic suppression, and unfavorable outcomes in hepatocellular carcinoma.

Summary: Liver cancer is one of the most common and hard-to-treat cancers in the world. Scientists recently studied a specific gene called EZH2 to see how it acts in liver cancer. They found that as the cancer grows from an early stage to a late stage, the chemical "tags" on this gene change. These changing tags seem to mess with the body's immune system and slow down how cells use energy. Because of this, doctors might be able to use the EZH2 gene to predict how the cancer will behave and eventually find new ways to treat it!